{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:53:14Z","timestamp":1793083994746,"version":"4.5.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,9,24]],"date-time":"2014-09-24T00:00:00Z","timestamp":1411516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2014,9,24]],"date-time":"2014-09-24T00:00:00Z","timestamp":1411516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>A key phenomenon in rheumatoid arthritis is the formation of lymphoid follicles in the inflamed synovial membrane. C-X-C motif chemokine 13 (CXCL13) is central in this process as it attracts C-X-C chemokine receptor type 5 (CXCR5)-expressing B cells and T follicular helper cells to the follicle. We here examine the role of CXCL13 and its association with disease in patients with treatment-na\u00efve early rheumatoid arthritis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Plasma samples from patients in the OPERA trial were examined for CXCL13 at treatment initiation and after 6 months of treatment with either methotrexate plus placebo (DMARD) (\n                      <jats:italic>n<\/jats:italic>\n                      = 37) or methotrexate plus adalimumab (DMARD + ADA) (\n                      <jats:italic>n<\/jats:italic>\n                      = 39). Treatment outcome was evaluated after 1 and 2 years. CXCL13 plasma levels in healthy volunteers (\n                      <jats:italic>n<\/jats:italic>\n                      = 38) were also examined.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Baseline CXCL13 plasma levels were increased in early rheumatoid arthritis patients in comparison with healthy volunteers. Also, plasma CXCL13 correlated positively with disease activity parameters; swollen joint count 28 (rho = 0.34) and 40 (rho = 0.39), visual analog score (rho = 0.38) and simplified disease activity index (rho = 0.25) (all\n                      <jats:italic>P<\/jats:italic>\n                      &lt;0.05). CXCL13 levels decreased a significantly twofold more in the DMARD + ADA group than in the DMARD group. Baseline CXCL13 plasma levels in the DMARD group correlated inversely with disease activity parameters; disease activity score in 28 joints, four variables, C-reactive protein based (DAS28CRP) (rho = 0.58,\n                      <jats:italic>P<\/jats:italic>\n                      &lt;0.05) at 12 months. High baseline CXCL13 was associated with remission (DAS28CRP less than 2.6) after 2 years.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In treatment-na\u00efve early rheumatoid arthritis patients, plasma CXCL13 levels were associated with joint inflammation. Furthermore, patients with high baseline plasma CXCL13 levels had an improved chance of remission after 2 years. We propose that high CXCL13 concentrations indicate recent onset of inflammation that may respond better to early aggressive treatment. Thus, high levels of CXCL13 could reflect the `the window of opportunity' for optimal treatment effect.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Clinicaltrial.gov\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\/show\/NCT00660647\">NCT00660647<\/jats:ext-link>\n                      . Registered 10 April 2008\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-014-0434-z","type":"journal-article","created":{"date-parts":[[2014,9,23]],"date-time":"2014-09-23T13:01:53Z","timestamp":1411477313000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["CXCL13 predicts disease activity in early rheumatoid arthritis and could be an indicator of the therapeutic `window of opportunity'"],"prefix":"10.1186","volume":"16","author":[{"given":"Stinne Ravn","family":"Greisen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen Kr\u00e6mmer","family":"Schelde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tue Kruse","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tue Wenzel","family":"Kragstrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Stengaard-Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merete Lund","family":"Hetland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"H\u00f8rslev-Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Junker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkel","family":"\u00d8stergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bent","family":"Deleuran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malene","family":"Hvid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,9,24]]},"reference":[{"key":"434_CR1","doi-asserted-by":"publisher","first-page":"3381","DOI":"10.1002\/art.21405","volume":"52","author":"YPMY Goekoop-Ruiterman","year":"2005","unstructured":"Goekoop-Ruiterman YPMY, de Vries-Bouwstra JKJ, Allaart CFC, van Zeben DD, Kerstens PJSMP, Hazes JMWJ, Zwinderman AHA, Ronday HKH, Han KHK, Westedt MLM, Gerards AHA, van Groenendael JHLMJ, Lems WFW, van Krugten MVM, Breedveld FCF, Dijkmans BACB: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005, 52: 3381-3390. 10.1002\/art.21405.","journal-title":"Arthritis Rheum"},{"key":"434_CR2","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1002\/eji.200425830","volume":"35","author":"A Manzo","year":"2005","unstructured":"Manzo A, Paoletti S, Carulli M, Blades MC, Barone F, Yanni G, FitzGerald O, Bresnihan B, Caporali R, Montecucco C, Uguccioni M, Pitzalis C: Systematic microanatomical analysis of CXCL13 and CCL21 in situ production and progressive lymphoid organization in rheumatoid synovitis. Eur J Immunol. 2005, 35: 1347-1359. 10.1002\/eji.200425830.","journal-title":"Eur J Immunol"},{"key":"434_CR3","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1371\/journal.pmed.0060001","volume":"6","author":"F Humby","year":"2009","unstructured":"Humby F, Bombardieri M, Manzo A, Kelly S, Blades MC, Kirkham B, Spencer J, Pitzalis C: Ectopic lymphoid structures support ongoing production of class-switched autoantibodies in rheumatoid synovium. PLoS Med. 2009, 6: e1-10.1371\/journal.pmed.0060001.","journal-title":"PLoS Med"},{"key":"434_CR4","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1002\/1529-0131(200008)43:8<1831::AID-ANR19>3.0.CO;2-6","volume":"43","author":"EJE Kroot","year":"2000","unstructured":"Kroot EJE, de Jong BAB, van Leeuwen MAM, Swinkels HH, van den Hoogen FHF, Hof MMV, van de Putte LBL, van Rijswijk MHM, van Venrooij WJW, van Riel PLP: The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 2000, 43: 1831-1835. 10.1002\/1529-0131(200008)43:8<1831::AID-ANR19>3.0.CO;2-6.","journal-title":"Arthritis Rheum"},{"key":"434_CR5","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3109\/14397595.2013.854051","volume":"24","author":"S Kubo","year":"2013","unstructured":"Kubo S, Saito K, Hirata S, Fukuyo S, Yamaoka K, Sawamukai N, Nawata M, Iwata S, Mizuno Y, Tanaka Y: Abatacept inhibits radiographic progression in patients with rheumatoid arthritis: a retrospective analysis of 6 months of abatacept treatment in routine clinical practice. The ALTAIR study. Mod Rheumatol. 2013, 24: 42-51. 10.3109\/14397595.2013.854051.","journal-title":"Mod Rheumatol"},{"key":"434_CR6","doi-asserted-by":"publisher","first-page":"650","DOI":"10.4049\/jimmunol.166.1.650","volume":"166","author":"K Shi","year":"2001","unstructured":"Shi K, Hayashida K, Kaneko M, Hashimoto J, Tomita T, Lipsky PE, Yoshikawa H, Ochi T: Lymphoid chemokine B cell-attracting chemokine-1 (CXCL13) is expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patients. J Immunol. 2001, 166: 650-655. 10.4049\/jimmunol.166.1.650.","journal-title":"J Immunol"},{"key":"434_CR7","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1002\/art.23966","volume":"58","author":"A Manzo","year":"2008","unstructured":"Manzo A, Vitolo B, Humby F, Caporali R, Jarrossay D, Dell'Accio F, Ciardelli L, Uguccioni M, Montecucco C, Pitzalis C: Mature antigen-experienced T helper cells synthesize and secrete the B cell chemoattractant CXCL13 in the inflammatory environment of the rheumatoid joint. Arthritis Rheum. 2008, 58: 3377-3387. 10.1002\/art.23966.","journal-title":"Arthritis Rheum"},{"key":"434_CR8","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1002\/art.38173","volume":"65","author":"S Kobayashi","year":"2013","unstructured":"Kobayashi S, Murata K, Shibuya H, Morita M, Ishikawa M, Furu M, Ito H, Ito J, Matsuda S, Watanabe T, Yoshitomi H: A distinct human CD4+ T cell subset that secretes CXCL13 in rheumatoid synovium. Arthritis Rheum. 2013, 65: 3063-3072. 10.1002\/art.38173.","journal-title":"Arthritis Rheum"},{"key":"434_CR9","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.4049\/jimmunol.0901690","volume":"183","author":"TD Chan","year":"2009","unstructured":"Chan TD, Gatto D, Wood K, Camidge T, Basten A, Brink R: Antigen affinity controls rapid T-dependent antibody production by driving the expansion rather than the differentiation or extrafollicular migration of early plasmablasts. J Immunol. 2009, 183: 3139-3149. 10.4049\/jimmunol.0901690.","journal-title":"J Immunol"},{"key":"434_CR10","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1002\/art.22939","volume":"56","author":"AM Wengner","year":"2007","unstructured":"Wengner AM, H\u00f6pken UE, Petrow PK, Hartmann S, Schurigt U, Br\u00e4uer R, Lipp M: CXCR5- and CCR7-dependent lymphoid neogenesis in a murine model of chronic antigen-induced arthritis. Arthritis Rheum. 2007, 56: 3271-3283. 10.1002\/art.22939.","journal-title":"Arthritis Rheum"},{"key":"434_CR11","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1093\/rheumatology\/keq337","volume":"50","author":"S Rosengren","year":"2011","unstructured":"Rosengren S, Wei N, Kalunian KC, Kavanaugh A, Boyle DL: CXCL13: a novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis. Rheumatology. 2011, 50: 603-610. 10.1093\/rheumatology\/keq337.","journal-title":"Rheumatology"},{"key":"434_CR12","doi-asserted-by":"publisher","first-page":"R103","DOI":"10.1186\/ar4552","volume":"16","author":"JD Jones","year":"2014","unstructured":"Jones JD, Hamilton BJ, Challener GJ, de Brum-Fernandes AJ, Cossette P, Liang P, Masetto A, M\u00e9nard HA, Carrier N, Boyle DL, Rosengren S, Boire G, Rigby WF: Serum C-X-C motif chemokine 13 is elevated in early and established rheumatoid arthritis and correlates with rheumatoid factor levels. Arthritis Res Ther. 2014, 16: R103-10.1186\/ar4552.","journal-title":"Arthritis Res Ther"},{"key":"434_CR13","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1136\/annrheumdis-2012-202735","volume":"73","author":"K Horslev-Petersen","year":"2013","unstructured":"Horslev-Petersen K, Hetland ML, Junker P, Podenphant J, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Schlemmer A, Dam MY, Hansen I, Horn HC, Ammitzboll CG, Jorgensen A, Krintel SB, Raun J, Johansen JS, Ostergaard M, Stengaard-Pedersen K, Slot O, Nielsen LK, Skjodt H, Majgaard O, Lorenzen T, Kowalski M, Johansen IL, Pedersen PM, Manilo N, Bliddal H: Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial. Ann Rheum Dis. 2013, 73: 654-661. 10.1136\/annrheumdis-2012-202735.","journal-title":"Ann Rheum Dis"},{"key":"434_CR14","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/2193-1801-2-263","volume":"2","author":"TW Kragstrup","year":"2013","unstructured":"Kragstrup TW, Vorup-Jensen T, Deleuran B, Hvid M: A simple set of validation steps identifies and removes false results in a sandwich enzyme-linked immunosorbent assay caused by anti-animal IgG antibodies in plasma from arthritis patients. SpringerPlus. 2013, 2: 263-10.1186\/2193-1801-2-263.","journal-title":"SpringerPlus"},{"key":"434_CR15","doi-asserted-by":"publisher","first-page":"R34","DOI":"10.1186\/ar3742","volume":"14","author":"S Bugatti","year":"2012","unstructured":"Bugatti S, Manzo A, Benaglio F, Klersy C, Vitolo B, Todoerti M, Sakellariou G, Montecucco C, Caporali R: Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs. Arthritis Res Ther. 2012, 14: R34-10.1186\/ar3742.","journal-title":"Arthritis Res Ther"},{"key":"434_CR16","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1002\/art.30273","volume":"63","author":"CM Meeuwisse","year":"2011","unstructured":"Meeuwisse CM, van der Linden MP, Rullmann TA, Allaart CF, Nelissen R, Huizinga TW, Garritsen A, Toes RE, van Schaik R, van der Helm-van Mil AH: Identification of CXCL13 as a marker for rheumatoid arthritis outcome using an in silico model of the rheumatic joint. Arthritis Rheum. 2011, 63: 1265-1273. 10.1002\/art.30273.","journal-title":"Arthritis Rheum"},{"key":"434_CR17","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1002\/art.23667","volume":"58","author":"I Rioja","year":"2008","unstructured":"Rioja I, Hughes FJ, Sharp CH, Warnock LC, Montgomery DS, Akil M, Wilson AG, Binks MH, Dickson MC: Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor \u03b1, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. Arthritis Rheum. 2008, 58: 2257-2267. 10.1002\/art.23667.","journal-title":"Arthritis Rheum"},{"key":"434_CR18","first-page":"76","volume":"47","author":"M Le Hir","year":"1995","unstructured":"Le Hir M, Bluethmann H, Kosco-Vilbois MH, Muller M, di Padova F, Moore M, Ryffel B, Eugster HP: Tumor necrosis factor receptor-1 signaling is required for differentiation of follicular dendritic cells, germinal center formation, and full antibody responses. J Inflamm. 1995, 47: 76-80.","journal-title":"J Inflamm"},{"key":"434_CR19","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.4049\/jimmunol.167.4.1920","volume":"167","author":"L Mandik-Nayak","year":"2001","unstructured":"Mandik-Nayak L, Huang G, Sheehan KC, Erikson J, Chaplin DD: Signaling through TNF receptor p55 in TNF-alpha-deficient mice alters the CXCL13\/CCL19\/CCL21 ratio in the spleen and induces maturation and migration of anergic B cells into the B cell follicle. J Immunol. 2001, 167: 1920-1928. 10.4049\/jimmunol.167.4.1920.","journal-title":"J Immunol"},{"key":"434_CR20","doi-asserted-by":"publisher","first-page":"330","DOI":"10.4049\/jimmunol.166.1.330","volume":"166","author":"Y Wang","year":"2001","unstructured":"Wang Y, Wang J, Sun Y, Wu Q, Fu YX: Complementary effects of TNF and lymphotoxin on the formation of germinal center and follicular dendritic cells. J Immunol. 2001, 166: 330-337. 10.4049\/jimmunol.166.1.330.","journal-title":"J Immunol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-014-0434-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-014-0434-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-014-0434-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-014-0434-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T12:21:35Z","timestamp":1728908495000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-014-0434-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,24]]},"references-count":20,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,10]]}},"alternative-id":["434"],"URL":"https:\/\/doi.org\/10.1186\/s13075-014-0434-z","relation":{},"ISSN":["1478-6354"],"issn-type":[{"value":"1478-6354","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,24]]},"assertion":[{"value":"9 March 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"434"}}